44 results about "Borrelia burgdorferi" patented technology

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

The present invention relates, e.g., to a Lactobacillus bacterium, which (1) expresses a recombinant polypeptide containing a lipoprotein signal sequence from the OspA protein of Borrelia burgdorferi, or an active variant of the leader sequence, operably linked to one or more heterologous polypeptide(s) of interest and / or (2) which comprises an expressible polynucleotide encoding a recombinant polypeptide, wherein the polynucleotide encodes a lipoprotein signal from the OspA protein of Borrelia burgdorferi, or an active variant thereof, which is operably linked to one or more heterologous polypeptide(s) of interest. In one embodiment, the heterologous polypeptide is from Yersinia pestis, the etiologic agent of plague. In another embodiment, the heterologous polypeptide is from Borrelia burgdorferi, the etiologic agent of Lyme disease. Also described are immunogenic compositions, such as live bacterial vaccines, comprising the bacterium; methods for eliciting an immune response against the polypeptide using the bacterium; and kits comprising the bacterium.

The invention relates to topical pharmaceutical compositions and methods related to Borrelia burgdorferi toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by Borrelia burgdorferi and in particular for the prevention of Lyme disease.

The present invention provides an accurate method to identify and quantify the Borrelia burgdorferi (Bb) antigen, the cause of Lyme Disease, in a sample of whole blood, body tissues and fluids of a subject, a human or animal subject. The qualitative method provides a quick, easy and accurate method of detection of the Bb antigen. The quantitative method allows for monitoring of treatment in conjunction with severity of clinical signs and symptoms.

The invention relates to both a sensitive method for the capture and detection of low-abundance Borrelia burgdorferi (Bb) bacterial antigens allowing for the diagnosis of Lyme Disease using standard immunoassays. Furthermore, this invention allows the antigen to be identified in a sample of urine, serum, or other biological fluids isolated from humans and animals. The invention provides a method to capture, concentrate, separate and specifically quantify the abundance of Bb antigens using immunoassays. The detection of Bb Outer Surface Protein A is presented as an example of the disclosed invention. High sensitivity levels, low cost and easily collected biofluids allow this technology to reach patients in clinics as well as POC applications for the early detection of Lyme disease prior to seroconversion. A kit containing necessary reagents and the method for diagnosis, monitoring or assessing lyme disease using an immunoassay such as an ELISA, western blot or RPPMA is disclosed.

In this application is described the characterization Borrelia burgdorferi lipoprotein BBK07, an in vivo expressed and surface-exposed immunogen. BBK07 expression in the infected hose can be detected at the RNA and protein level as early as the first week of infection. Therefore, described is the use of BBK07 antigen and immunogenic epitopes as well as bbk07 nucleotides in methods and kits for the diagnosis of Lyme disease.

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi and antigenic subunits and a suitable carrier.

The invention relates to the technical field of molecular biomedicine, in particular to a PCR (Polymerase Chain Reaction) detection kit for cat and / or dog pathogens, a detection method and application. The kit is used for detecting canine distemper virus, canine influenza A virus, canine parainfluenza virus, canine parvovirus, canine coronavirus, canine rotavirus, canine babesia, canine ascaris, canine Ehrlichia, canine brucella, rabies virus, borrelia burgdorferi, reference gene ACTB, feline herpes virus, feline calicivirus and feline parvovirus. The kit comprises primers and probes of feline coronavirus, feline immunodeficiency virus, feline leukemia virus, feline mycoplasma, feline mycoplasma, feline chlamydia, giardia, toxoplasma, bartonella and reference gene GAPDH, collected DNA and RNA are added into the kit, a real-time fluorescence PCR instrument is adopted for PCR reaction, FAM, HEX, ROX and CY5 fluorescence signals are collected in each cycle, analysis of related pathogens is carried out, and the kit can be used for detecting the feline and the canine. Compared with a traditional detection method, the method has the advantages of higher specificity and higher sensitivity.

Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition

The present disclosure provides methods for detecting early Lyme disease. The present disclosure provides a biosignature indicative of the presence or absence of Borrelia burgdorferi infection.

The invention discloses a piece of test paper for detecting borrelia burgdorferi antibodies, a test paper preparation method and a kit. The invention discloses the test paper for detecting the borrelia burgdorferi antibodies. The test paper consists of a sample pad, a Fe3O4 magnetic nano particle carrier pad, a nitrocellulose film and a water absorption pad which are overlapped in sequence and are attached to a bottom lining clamp, wherein the Fe3O4 magnetic nano particle carrier pad is a glass fiber film on which staphylococcus aureus A protein (SPA) labeled magnetic nano particles are fixed; the nitrocellulose film is provided with a detection band and a quality control band; the detection band is wrapped by borrelia burgdorferi antigens; the quality control band is wrapped by antibodies combined with SPA. The detection kit consists of the detection test paper and peroxidase substrate developing liquid and is used for detecting the borrelia burgdorferi antibodies. The kit can effectively detect the borrelia burgdorferi antibodies; a detection result is stable and reliable; the specificity is high, and the sensitivity is high; compared with a piece of general colloid detection test paper, the test paper has the advantages that the test paper sensitivity is improved by 100 times, and the operation is simple; detectors are not needed; the detection result can be obtained by eyes.

The present invention relates to methods for culturing spirochetes, in particular Borrelia burgdorferi. The present invention also provides methods of identifying spirochetes present in a biological sample. The present invention further provides methods of diagnosing diseases cause by a spirochete infection, such as Lyme disease, syphilis, and multiple sclerosis. The present invention further provides methods for identifying spirochete susceptibilities to antimicrobials and antimicrobial compositions and cocktails. The present invention also provides methods for treating subjects suspected of having a spirochete infection.

Two Borrelia burgdorferi recombinant proteins were expressed in E. coli. These two proteins were generated from (a) the full length dbpA gene combined with the invariable region 6 of the VlsE gene (dbpA / C6), and (b) the full length OspC gene combined with the coding sequence for amino acids 1-121 of the E. coli maltose binding protein gene (OspC / MBP). Methods of using these recombinant proteins for detecting anti-Borrelia burgdorferi antibodies in patient sera and diagnosis of Lyme Disease are described.

The invention discloses a borrelia BSK storage liquid culture medium and a single colony separating and purifying method and application thereof. The borrelia BSK storage liquid culture medium comprises CMRL-1066, bovine serum albumin V, new peptone, hydroxyethyl piperazine ethanesulfonic acid, sodium citrate, glucose, yeast powder, sodium bicarbonate, sodium pyruvate, acetyl glucosamine, rabbit serum, sodium hydroxide, and the like. The single colony separating and purifying method comprises the following steps of: preparing the BSK storage liquid culture medium, preparing sepharose gel, sterilizing at high pressure, gradually melting, uniformly mixing with the BSK storage liquid culture medium in proportion, and pouring to prepare a lower solid culture medium; mixing a borrelia burgdorferi bacterium suspension diluted in a gradient way and the BSK storage liquid culture medium, pouring into an upper culture medium so that a macroscopic single colony appears; raising the single colony by using a toothpick, inspecting by using a dark-field microscope to observe a representative burgdorferi bacterium strain. The method disclosed by the invention has the advantages of easiness and fastness for operation and clarity in result. According to the invention, the representative burgdorferi bacterium strain is uniform in genetic background without heterogeneity, suitable for subsequent scientific research and used as a standard strain.